查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1750872

CAR-T細胞治療市場規模、佔有率、趨勢分析報告：按產品、適應症、最終用途、地區、細分市場預測，2025-2030年

CAR T-cell Therapy Market Size, Share & Trends Analysis Report By Product (Abecma, Breyanzi, Carvykti, Kymriah), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End-use, By Region and Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

CAR-T細胞治療市場的成長與趨勢

根據 Grand View Research, Inc. 的最新報告，全球 CAR-T 細胞療法市場規模預計到 2030 年將達到 159.7 億美元，2025 年至 2030 年的複合年成長率為 22.2%。

CAR-T細胞療法透過利用患者的免疫系統殺死癌細胞，為淋巴瘤、多發性骨髓瘤和白血病等血癌的治療帶來了模式轉移。新興國家中，多發性骨髓瘤等癌症類型的發生率不斷上升，推動市場的發展。強而有力的監管支持，例如產品核可和集中的藥物研發管線，也進一步增強了該產業的發展。例如，根據美國國家醫學圖書館2023年4月發布的報告，全球約有310項與CAR-T細胞相關的研究正在進行，涵蓋早期I期、I期和II期。

為了涵蓋全球治療，各公司正在建立策略聯盟並進行地理擴張。因此，各公司正在採取策略，在尚未找到血癌潛在治療方法和治療方案的國家擴大地域覆蓋範圍。例如，2022年8月31日，吉利德旗下的醫療公司Kite宣布將其CAR-T細胞療法擴展到沙烏地阿拉伯、巴西和新加坡。該公司報告稱，新加坡的非何傑金氏淋巴瘤(NHL)發生率超過1,000例，而沙烏地阿拉伯約有1,700例確診病例。同樣，巴西每年約有12,000例非何傑金氏淋巴瘤病例。

COVID-19疫情為患者實施CAR-T細胞療法帶來了挑戰，尤其是在疫情初期，許多醫院和診所都擠滿了COVID-19患者。許多醫院不得不推遲或停止包括CAR-T細胞療法在內的選擇性治療，以節省資源用於COVID-19患者。此外，由於CAR-T細胞療法存在嚴重的副作用，例如細胞激素釋放症候群（CRS），可能導致發燒、低血壓和器官損傷，這些症狀與COVID-19類似，因此治療也存在問題。

新興國家的醫院和癌症治療中心擴大採用CAR-T細胞療法。這些中心透過經濟高效且省時的癌症治療，推動了市場的整體成長。例如，2022年8月，墨西哥癌症治療中心免疫療法研究所 (Immunotherapy Institute) 開始營運，為美國和加拿大的患者提供CAR-T細胞療法。同樣，在以色列，由於整個治療過程都在醫院內部完成，治療大約可在10天內完成，從而顯著節省了成本。

新興國家缺乏熟練的專業人員以及高成本仍然是市場成長的挑戰。然而，隨著人們對技術先進的CAR-T細胞療法的認知度不斷提高以及核准，預計將緩解這些挑戰，並在預測期內促進市場成長。根據美國癌症治療中心的數據，截至2023年，美國FDA已核准六種CAR-T細胞療法用於治療血液系統癌症。

CAR-T細胞治療市場報告重點

  • 根據產品情況，Yescarta（axicabtagene ciloleucel）在 2024 年佔據了 50.0% 的市場佔有率。 Yescarta 的高吸收率歸因於其良好的性能和復發性 B 細胞大淋巴瘤成人患者的生存率提高。
  • 按適應症分類，淋巴瘤在2024年佔據了CAR-T細胞療法市場的最大佔有率。該領域的高市場滲透率歸因於該疾病在全球範圍內的高發病率。此外，市場參與者對消除CD-19抗原產品的強烈關注也是推動其成長的因素。
  • 根據最終用途，醫院部門在 2024 年佔據 CAR-T 細胞治療產業的最大佔有率。此外，由於醫院實驗室加快了這一進程，它們正在獲得很高的佔有率。
  • 2024 年，北美佔最大佔有率，為 62.1%。佔有率較大的主要原因是患者數量龐大，由於核准速度快、醫療保險覆蓋範圍廣，整體上可以獲得常見但複雜的醫療保健。

目錄

第1章調查方法與範圍

第2章執行摘要

3. CAR-T細胞療法市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/支持市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • CAR-T細胞療法市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 CAR-T細胞療法市場：依產品進行評估與趨勢分析

  • 產品細分儀表板
  • CAR-T細胞療法市場：產品差異分析
  • 2018-2030年全球CAR-T細胞治療市場規模及產品趨勢分析
  • Abecma（Idecabtagemic 雙透明細胞）
  • Breyanzi（lysocabtagene malareucel）
  • Carvykti（Silta Cavtagene Autoreucel）
  • Kymriah（Tisagenleclerc）
  • Tecartus（Brexucabtagene Autoreucel）
  • Yescarta（Axicocabtagenesis Siloreucel）
  • 其他

第5章：CAR-T細胞療法市場：按適應症的估計和趨勢分析

  • 疾病適應症細分儀表板
  • CAR-T細胞治療市場：適應症差異分析
  • 2018-2030年全球CAR-T細胞治療市場規模及趨勢分析（依適應症）
  • 白血病
  • 淋巴瘤
  • 多發性骨髓瘤
  • 其他

第6章 CAR-T細胞治療市場：依最終用途的估計和趨勢分析

  • 產品細分儀表板
  • CAR-T細胞療法市場：最終用途差異分析
  • 2018-2030年全球CAR-T細胞治療市場規模及趨勢分析（依最終用途）
  • 醫院
  • 癌症治療中心

第7章 CAR-T細胞治療市場：區域、估計和趨勢分析

  • 區域市場儀表板
  • 2024 年及 2030 年區域市場佔有率分析
  • CAR-T細胞治療市場（按地區）
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
  • 亞太地區
    • 日本
    • 中國
  • 其他國家

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • Key Company Heat Map Analysis, 2024
  • 公司簡介
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Gilead Sciences, Inc.
    • Johnson &Johnson Services, Inc.
    • JW Therapeutics（Shanghai）Co., Ltd.
    • bluebird bio, Inc.
    • Merck &Co., Inc.
    • Sangamo Therapeutics
    • Sorrento Therapeutics, Inc.
    • GSK plc.
Product Code: GVR-4-68040-090-4

CAR T-cell Therapy Market Growth & Trends:

The global CAR T-cell therapy market size is estimated to reach USD 15.97 billion by 2030, expanding at a CAGR of 22.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. CAR T-cell therapy presents a paradigm shift in the treatment of blood cancers such as lymphoma, multiple myeloma, and leukemia by utilizing the patient's immune system to terminate cancer cells. The rising prevalence of cancer types such as multiple myeloma in developing countries is driving the market. Rampant regulatory support in the form of product approvals and an intensive product pipeline of drugs further strengthens the industry. For instance, as per the U.S. National Library of Medicine April 2023, around 310 studies pertinent to CAR T-cells are being conducted across early phase I, phase I, and phase II in various parts of the world.

Various players are entering into strategic partnerships along with geographic expansion to necessitate therapy coverage across the world. Thereby, companies are adopting strategies to increase the geographical footprint in countries without access to potential cures or treatments for blood cancers. For instance, on August 31, 2022, Kite, a medical company operating under Gilead announced the expansion of CAR T-cell therapy in regions of Saudi Arabia, Brazil, and Singapore. The company reported an occurrence of 1000 or higher cases of non-Hodgkin lymphoma (NHL) in Singapore, while around 1700 cases of the disease are diagnosed in Saudi Arabia. Similarly, in Brazil, around 12000 cases of NHL are found each year.

The COVID-19 pandemic has made it difficult to administer CAR T-cell therapy to patients, particularly in the early stages of the pandemic when many hospitals and clinics were overwhelmed with COVID-19 patients. Many hospitals had to postpone or cancel elective procedures, including CAR T-cell therapy, to free up resources for COVID-19 patients. In addition, CAR T-cell therapy has significant side effects, including cytokine release syndrome (CRS), which can cause fever, low blood pressure, and organ damage which mimics the symptoms of COVID-19, thereby, curating problems to treat for condition.

Moreover, hospitals and cancer care centers emerging in developing countries are progressing with the adoption of CAR T-cells. These centers thrive as cost and time-efficient cancer treatments allow the market to grow holistically. For instance, in August 2022, Immunotherapy Institute, a cancer treatment center in Mexico began operations to offer CAR T-cells for American and Canadian patients. Similarly, in Israel, the therapy can be expedited in about 10 days owing to the entire process being conducted in-house, with notable cost reductions.

The lack of skilled professionals in emerging nations coupled with the high cost associated with the therapy remain challenges to market growth. However, rising awareness and increasing approvals for technologically advanced CAR T-cell therapy are anticipated to mitigate these challenges and contribute to market growth over the forecast period. According to Cancer Treatment Centers of America, six CAR T-cell therapies were approved by U.S. FDA for the treatment of blood cancers as of 2023.

CAR T-cell Therapy Market Report Highlights:

  • By product, the Yescarta (axicabtagene ciloleucel) segment dominated the market with a share of 50.0% in 2024. The high usage of Yescarta can be attributed to strong performance and improved survivability in adults suffering from relapsed B-cell large lymphoma
  • The lymphoma segment held the largest CAR T-cell therapy market share in 2024. The high penetration of the market segment owes itself to the significant prevalence of the condition across the world. Additionally, the strong product focus by market players to eliminate the CD-19 antigen drives growth
  • By end-use, the hospital segment held the largest share of CAR T-cell therapy industry in 2024 due to the robust presence of fiscal and operational resources. Additionally, in-house labs for hospitals expedite the process faster, helping to gain a strong share
  • North America accounted for the largest share of 62.1% in 2024. The primary reason for a sizable share can be attributed to the patient volume and overall access to general and complex healthcare, with speedy approvals and robust medical insurance coverage

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease Indication
    • 1.2.3. End Use
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and Forecasts Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product Outlook
    • 2.2.2. Disease indication Outlook
    • 2.2.3. End Use Outlook
    • 2.2.4. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. CAR T-cell Therapy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. CAR T-cell Therapy Market Analysis tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Technological Landscape
      • 3.3.2.3. Economic Landscape

Chapter 4. CAR T-cell Therapy Market: Product Estimates & Trend Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. CAR T-cell Therapy Market: Product Movement Analysis
  • 4.3. Global CAR T-cell Therapy Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Million)
  • 4.4. Abecma (idecabtagene vicleucel)
    • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5. Breyanzi (lisocabtagene maraleucel)
    • 4.5.1. ket Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.6. Carvykti (ciltacabtagene autoleucel)
    • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.7. Kymriah (tisagenlecleucel)
    • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.8. Tecartus (brexucabtagene autoleucel)
    • 4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.9. Yescarta (axicabtagene ciloleucel)
    • 4.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. CAR T-cell Therapy Market: Disease Indication Estimates & Trend Analysis

  • 5.1. Disease Indication Segment Dashboard
  • 5.2. CAR T-cell Therapy Market: Disease Indication Movement Analysis
  • 5.3. Global CAR T-cell Therapy Market Size & Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)
  • 5.4. Leukemia
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Lymphoma
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6. Multiple Myeloma
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. CAR T-cell Therapy Market: End Use Estimates & Trend Analysis

  • 6.1. Product Segment Dashboard
  • 6.2. CAR T-cell Therapy Market: End-use Movement Analysis
  • 6.3. Global CAR T-cell Therapy Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5. Cancer Treatment Centers
    • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. CAR T-cell Therapy Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. Continuous Bioprocessing Market By Region: Key Takeaways
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key Country Dynamics
      • 7.4.1.2. Regulatory Framework/ Reimbursement Structure
      • 7.4.1.3. Competitive Scenario
      • 7.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework/ Reimbursement Structure
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Germany
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Regulatory Framework/ Reimbursement Structure
      • 7.5.1.3. Competitive Scenario
      • 7.5.1.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework/ Reimbursement Structure
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Regulatory Framework/ Reimbursement Structure
      • 7.6.1.3. Competitive Scenario
      • 7.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework/ Reimbursement Structure
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.7. Rest of World
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Regulatory Framework/ Reimbursement Structure
      • 7.7.1.3. Competitive Scenario
      • 7.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key Company Heat Map Analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. Bristol-Myers Squibb Company
      • 8.4.1.1. Company Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Company Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Gilead Sciences, Inc.
      • 8.4.3.1. Company Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Johnson & Johnson Services, Inc.
      • 8.4.4.1. Company Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. JW Therapeutics (Shanghai) Co., Ltd.
      • 8.4.5.1. Company Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. bluebird bio, Inc.
      • 8.4.6.1. Company Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Merck & Co., Inc.
      • 8.4.7.1. Company Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Sangamo Therapeutics
      • 8.4.8.1. Company Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Sorrento Therapeutics, Inc.
      • 8.4.9.1. Company Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. GSK plc.
      • 8.4.10.1. Company Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 3 North America CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 5 North America CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 6 U.S. CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 7 U.S. CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 8 U.S. CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 10 Canada CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 11 Canada CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Europe CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 13 Europe CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 14 Europe CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 15 Europe CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Germany CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 17 Germany CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 18 Germany CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 19 UK CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 20 UK CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 21 UK CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Asia Pacific CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 23 Asia Pacific CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 24 Asia Pacific CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 25 Asia Pacific CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Japan CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 27 Japan CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 28 Japan CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 29 China CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 30 China CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 31 China CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Rest of World CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 33 Rest of World CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 34 Rest of World CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 35 Rest of World CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 CAR T-cell therapy market: Market outlook
  • Fig. 10 CAR T-cell therapy competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 CAR T-cell therapy market driver impact
  • Fig. 16 CAR T-cell therapy market restraint impact
  • Fig. 17 CAR T-cell therapy market strategic initiatives analysis
  • Fig. 18 CAR T-cell therapy market: Product movement analysis
  • Fig. 19 CAR T-cell therapy market: Product outlook and key takeaways
  • Fig. 20 Abecma (idecabtagene vicleucel) market estimates and forecast, 2018 - 2030
  • Fig. 21 Breyanzi (lisocabtagene maraleucel) market estimates and forecast, 2018 - 2030
  • Fig. 22 Carvykti (ciltacabtagene autoleucel) market estimates and forecast, 2018 - 2030
  • Fig. 23 Kymriah (tisagenlecleucel) market estimates and forecast, 2018 - 2030
  • Fig. 24 Tecartus (brexucabtagene autoleucel) market estimates and forecast, 2018 - 2030
  • Fig. 25 Yescarta (axicabtagene ciloleucel) market estimates and forecast, 2018 - 2030
  • Fig. 26 Other market estimates and forecast, 2018 - 2030
  • Fig. 27 CAR T-cell therapy market: Disease indication movement analysis
  • Fig. 28 CAR T-cell therapy market: Disease indication outlook and key takeaways
  • Fig. 29 Leukemia market estimates and forecasts, 2018 - 2030
  • Fig. 30 Lymphoma market estimates and forecasts,2018 - 2030
  • Fig. 31 Multiple Myeloma market estimates and forecasts, 2018 - 2030
  • Fig. 32 Other market estimates and forecasts, 2018 - 2030
  • Fig. 33 CAR T-cell therapy market: End use movement analysis
  • Fig. 34 CAR T-cell therapy market: End use outlook and key takeaways
  • Fig. 35 Hospitals CAR T-cell therapy market estimates and forecast, 2018 - 2030
  • Fig. 36 Cancer Treatment Centers CAR T-cell therapy estimates and forecast, 2018 - 2030
  • Fig. 37 Global CAR T-cell therapy market: Regional movement analysis
  • Fig. 38 Global CAR T-cell therapy market: Regional outlook and key takeaways
  • Fig. 39 North America market estimates and forecasts, 2018 - 2030
  • Fig. 40 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 41 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 42 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 43 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 44 UK market estimates and forecasts, 2018 - 2030
  • Fig. 45 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 46 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 47 China market estimates and forecasts, 2018 - 2030
  • Fig. 48 Rest of World market estimates and forecasts, 2018 - 2030